Dataset from A Phase 1b, Open-Label, Dose-Escalation Study of MLN4924 Plus Azacitidine in Treatment-Naïve Patients With Acute Myelogenous Leukemia Who Are 60 Years or Older
收藏NIAID Data Ecosystem2026-05-10 收录
下载链接：
https://doi.org/10.25934/PR00008399
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this study is to establish the maximum tolerated dose (MTD), and to assess the
safety and tolerability of MLN4924 (pevonedistat) in combination with azacitidine in
treatment naive participants with AML who were 60 years of age or older.
创建时间：
2025-10-01
